One clinical-grade test, a validated bioinformatics suite built and proven over two years, and the engineers who deploy it inside your operation — so the answer held in the genome reaches the person making the decision. One partner, from sample to decision.
Turning a genome into a decision takes three things most organizations don't have — and a general-purpose model can't supply.
Affordably, across an entire population, at clinical grade — not just the patients who happen to get referred.
Validated interpretation of what the genome actually says. It takes years of science to build and prove — not months of engineering.
Getting the answer into the system and in front of the person, at the moment the decision is made.
A general model reads, plans, and writes well. It can't do the scientific computation in the middle — and that is where the answer lives. The Kure supplies validated bioinformatics modules that do that computation the same way every time, with a known error rate, plus the connections that put their findings into your work.
One low-cost, clinical-grade test for the whole population — or start from the data you already hold.
Bring the biological data together with its clinical, experimental, or operational context.
Give it the validated scientific modules the task requires.
Put the findings into reviews, investigations, documentation, and follow-up.
Validated, not guessed. Every module runs the same way every time, with a known error rate.
Our engineers live inside your organization, wire it into your real systems, and stay until it works. Clinicians and operators own every consequential decision.
Built and validated over two years. It takes a genome from raw data to a finished clinical report — for the individual and for the population.
Which drug, which dose, for this genome.
Find the single variants that matter.
Grade every variant pathogenic, benign, or uncertain — by the clinical standard.
Genomics, labs, and clinical data resolved into one number a clinician can act on.
Rank a whole population by risk, so administrators know who to screen, what to stock, and where to act first.
The module writes the report a clinician reads and a lab director signs — not just the result.
Several of the suite's core algorithms build on published research conducted at Scripps Research. Our team engineered and validated the full suite independently — two years of work before its first deployment.
The methods behind the suite are published in the peer-reviewed literature — external validation, not a claim in a pitch.
Every sample is processed through CLIA/CAP-certified laboratory partners.
Variants are classified to the ACMG standard used by clinical genetics labs.
Every module reports a quantified error rate — the discipline a clinical decision demands.
Founded by physician-scientists, genomics researchers, and product leaders behind category-defining consumer technology — trained at Stanford, MIT, and Berkeley, with $1B+ in prior revenue and multiple exits.
We begin where one budget pays for both the data and the outcome. A single organization owns the population for years, runs the formulary, fills the prescriptions, and pays for every adverse reaction — and prescribes heavily in exactly the drug classes where genotype matters most.
Standing populations the system screens, prescribes for, and pays outcomes on.
One authority owning care for a long-tenure population.
Federally served populations with concentrated, longitudinal need.
Integrated payers that own both the formulary and the outcome.
Generate identity leads from biological relationships; investigate exposure-associated health changes.
Combine biological measurements with clinical and environmental context for medical planning, recovery, and outbreak investigation.
Connect experimental evidence to treatment response, plan follow-up experiments, and troubleshoot lab variability.
Genomes first — then proteins, images, physiological signals, pathogens, and experimental data. The same approach, applied to new biology.
One clinical-grade test per member of the population, priced per sample.
Integration and configuration of the first application inside your systems.
Continued use of the modules and the AI application, with updates and support.
Further applications, populations, and facilities — and Kure modules embedded in partners' services.
The scientific core is built once. Each deployment adds connectors and components we reuse for the next customer.
If you own a population's data and its outcomes, we'll show you what a validated genomics layer puts in front of your decision-makers.
hello@thekure.ai